- Home
- GUTS vs CTMX Comparison
GUTS vs CTMX Comparison
Compare GUTS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- CTMX
- Stock Information
- Founded
- GUTS 2010
- CTMX 2008
- Country
- GUTS United States
- CTMX United States
- Employees
- GUTS N/A
- CTMX N/A
- Industry
- GUTS
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- CTMX Health Care
- Exchange
- GUTS NYSE
- CTMX Nasdaq
- Market Cap
- GUTS 58.8M
- CTMX 60.7M
- IPO Year
- GUTS 2024
- CTMX 2015
- Fundamental
- Price
- GUTS $1.75
- CTMX $2.10
- Analyst Decision
- GUTS Buy
- CTMX Buy
- Analyst Count
- GUTS 1
- CTMX 2
- Target Price
- GUTS $10.00
- CTMX $2.50
- AVG Volume (30 Days)
- GUTS 264.4K
- CTMX 9.0M
- Earning Date
- GUTS 05-13-2025
- CTMX 05-12-2025
- Dividend Yield
- GUTS N/A
- CTMX N/A
- EPS Growth
- GUTS N/A
- CTMX 128.27
- EPS
- GUTS N/A
- CTMX 0.49
- Revenue
- GUTS $93,000.00
- CTMX $147,557,000.00
- Revenue This Year
- GUTS N/A
- CTMX N/A
- Revenue Next Year
- GUTS N/A
- CTMX N/A
- P/E Ratio
- GUTS N/A
- CTMX $5.09
- Revenue Growth
- GUTS N/A
- CTMX 23.81
- 52 Week Low
- GUTS $0.87
- CTMX $0.40
- 52 Week High
- GUTS $7.89
- CTMX $2.81
- Technical
- Relative Strength Index (RSI)
- GUTS 62.61
- CTMX 74.17
- Support Level
- GUTS $1.47
- CTMX $0.91
- Resistance Level
- GUTS $1.79
- CTMX $2.55
- Average True Range (ATR)
- GUTS 0.15
- CTMX 0.21
- MACD
- GUTS 0.04
- CTMX 0.17
- Stochastic Oscillator
- GUTS 78.69
- CTMX 77.92
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.